MilliporeSigma (Merck KGaA) to Acquire HUB Organoids Holding B.V.

ORHub, Inc. Acquires PUR Biologics, LLC

April 25, 2022

Medical Devices

ORHub, Inc. (OTC: ORHB) purchased 100% of the equity interest and assets of PUR Biologics, LLC, acquiring proprietary regenerative therapeutic and bone regeneration product technologies. The acquisition enables ORHub to enter the global medical device market and expand its regenerative therapeutic capabilities as it updates corporate branding and prepares for an audit and potential up-listing.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Rigaku Corporation Acquires MILabs B.V.

August 2, 2021

Medical Devices

Rigaku Corporation acquired all issued shares of MILabs B.V., a Netherlands-based manufacturer of preclinical PET, SPECT, CT and optical imaging systems, closing on August 2, 2021. The deal expands Rigaku's entry into the life sciences and pre-clinical imaging market by combining MILabs' multi-modality imaging capabilities with Rigaku's X-ray imaging and global sales and service network.

Merck Acquires Imago BioSciences for $1.35 Billion

November 21, 2022

Biotechnology

Merck (MSD) entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Imago BioSciences in an all-cash deal valued at approximately $1.35 billion (=$36.00 per share). Merck will commence a tender offer for all outstanding shares, with the transaction expected to close in the first quarter of 2023, subject to customary conditions.